title: Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre , Melbourne , Australia.
authors.forename: Edward
authors.initials: E
authors.lastname: Chew
authors.forename: Karin
authors.initials: K
authors.lastname: Thursky
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018890:Chemoprevention; D006509:Hepatitis B / Q000517:prevention & control / Q000821:virology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D014775:Virus Activation / Q000187:drug effects*; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000188:drug therapy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine; D000069283:Rituximab